Showing results (31-40 of 67) with videos related to
Sort By:
Pageof 7
Journal of Medicinal Chemistry|May 22, 2009
Design, synthesis, and evaluation of N-acyl modified sialic acids as inhibitors of adenoviruses causing epidemic keratoconjunctivitisSusanne Johansson, Emma Nilsson, Weixing Qian, et al.Pharmacology Research & Perspectives|May 20, 2022
Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participantsSusanne Johansson, David Han, Thomas Hunt, et al.Clinical Pharmacokinetics|July 9, 2003
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatranUlf G Eriksson, Susanne Johansson, Per-Ola Attman, et al.The Journal of Pharmacology and Experimental Therapeutics|June 2, 2021
In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug TransportersV Sashi Gopaul, Anna Vildhede, Tommy B Andersson, et al.Journal of Virology|January 15, 2004
Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infectionNicole G Newcombe, E Susanne Johansson, Gough Au, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 2016
Managing the Risk of CYP3A Induction in Drug Development: A Strategic ApproachBarry C Jones, Helen Rollison, Susanne Johansson, et al.Journal of Clinical Pharmacology|March 31, 2004
The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcoholTroy C Sarich, Susanne Johansson, Kajs-Marie Schützer, et al.Biochemical and Biophysical Research Communications|April 20, 2004
Cell culture propagation and biochemical analysis of the Ljungan virus prototype strainE Susanne Johansson, Jens-Ola Ekström, Darren R Shafren, et al.British Journal of Clinical Pharmacology|December 12, 2022
Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modellingJoanna Parkinson, Corina Dota, Christian Källgren, et al.Clinical Pharmacokinetics|July 9, 2003
Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactionsEva Bredberg, Tommy B Andersson, Lars Frison, et al.Pageof 7